VENTION ADVANCED TECHNOLOGIES acquired by NORDSON CORPORATION

This transaction involves Charterhouse successfully acquiring a controlling majority stake in SERB. The operation is meticulously structured to perfectly align with the target's existing executive leadership. The historical controlling shareholder and the incumbent management team are significantly reinvesting their proceeds to retain a robust equity position while continuing to lead day-to-day operations. Charterhouse utilizes its latest flagship investment vehicle to capitalize this partnership. The primary strategic rationale underpinning the deal is to massively accelerate SERB's developmental roadmap. The freshly injected capital and strategic guidance will be explicitly deployed to fuel ongoing geographic expansion and aggressively pursue the continuous acquisition of complementary specialty pharmaceutical products and synergistic businesses.

Orchestrating a major shift in the European medtech landscape, this majority buyout extracts ELITechGroup from its previous financial framework to catalyze an aggressive international scaling phase. The strategic rationale centers on leveraging the target's specialized molecular diagnostic footprint to navigate the maturing global healthcare sector. Rather than a simple portfolio addition, this move represents a calculated bet on the structural transition toward decentralized laboratory automation and precision pathology.

The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5.318 billion. This price represents a premium of roughly 49% over the unaffected share price from December 2016. The deal concludes a highly competitive bidding process (where Advent International was also a contender). The strategic rationale is to delist STADA to allow for a more aggressive long-term growth strategy, unburdened by quarterly public reporting.

Ardian, an independent private investment firm, has entered into exclusive negotiations to acquire a majority stake in Unither Pharmaceuticals, a global leader in the Contract Development and Manufacturing Organization (CDMO) sector. Ardian submitted a firm offer to Equistone, which leads a consortium of sellers including historical shareholders Parquest Capital and CM-CIC Investissement.

Ecolab has completed the acquisition of 100% of Laboratoires Anios from Ardian and the Letartre family. This transaction represents a definitive exit for the private equity firm Ardian, which had supported the founding family in a 2013 LBO following a previous ownership cycle by Air Liquide. The strategic rationale for Ecolab is to establish a dominant foothold in the European hospital disinfection market, a segment where it was previously underrepresented. For Anios, the merger provides a global springboard, particularly to accelerate its expansion into the Chinese market. Over the three years of Ardian’s ownership, Anios achieved a 25% increase in revenue and a 55% jump in EBITDA, driven by a series of five strategic "bolt-on" acquisitions.

Ardian entered into exclusive negotiations to acquire a majority stake in Lagarrigue from Azulis Capital. The transaction allowed the management team to reinforce their equity stake. Historical minority investor iXO Private Equity reinvested, while Azulis Capital, Galia Gestion, and BNP Paribas Developpement fully exited. This deal marked the transition from a regional SME to a national leader with international ambitions. The roadmap focused on external growth and digital transformation.

On September 19, 2016, ArchiMed completed the acquisition of a majority stake in Polyplus Transfection, a prominent player in the biologics delivery space. The transaction was executed as a proprietary deal, seamlessly completed outside of any formal auction process, and was heavily supported by the existing management team. This strategic move represents a textbook platform investment for the private equity firm, executed through its Med 1 fund, capitalizing on their deep sector expertise. The strategic rationale behind this transaction is deeply rooted in the strong secular growth currently observed across biologics-based therapeutics and cell therapies. By acquiring this niche champion, the firm aims to leverage its extensive global healthcare network to accelerate international expansion and push proprietary product development into a higher gear. The deal is expected to be highly value-accretive, combining vast financial resources and operational capabilities with specialized proprietary transfection technology. Market implications are substantial, signaling increased sector consolidation within the highly fragmented life sciences supply chain and highlighting the premium placed on specialized reagent manufacturers.

PAI Partners has entered into a definitive agreement to acquire 100% of Atos Medical from EQT. This secondary LBO represents the 10th investment of the PAI Europe VI fund and marks the exit of EQT, which had overseen a period where the company doubled in size within five years. The current management team, led by CEO Claus Bjerre, remains in place to lead the next phase of the company's development under PAI's sponsorship. The strategic rationale for the acquisition is centered on the underpenetrated nature of the global laryngectomy market and the scalability of Atos Medical's direct-to-consumer model. PAI intends to leverage its healthcare sector capabilities to accelerate the company's transformational strategy, focusing on increased R&D investment and a broader global sales footprint. The deal is underpinned by the target's exceptional financial performance, including a 30% revenue growth in 2015 and industry-leading margins.

The third LBO of Acteon marks a definitive strategic shift toward institutional global leadership, orchestrated by Bridgepoint Development Capital alongside Raise Investissement and Euro Private Equity. The strategic rationale for this transaction centers on an "innovation-acceleration" play, merging the group’s industry-leading technical operational depth in ultrasonics with the sponsor’s extensive international commercial infrastructure. This structural alignment provides the organization with the scientific talent and logistical hardware required to address the increasing complexity of the global digital dentistry market. This operation allows the group to execute a definitive structural expansion of its product suite, particularly through a renewed emphasis on research and development following several years of stabilization. By incorporating the sponsor’s strategic discipline, the group is now positioned to leverage its recognized leadership in high-frequency imaging to deepen its presence in high-stakes markets such as North America and Asia.

PAI Partners has entered into a definitive agreement to acquire Ethypharm from Astorg Partners and its Belgian co-investor Sofina. The transaction followed a competitive auction process managed by Rothschild & Cie, where PAI reportedly outbid other major private equity firms and international pharmaceutical groups. The operation marks a successful exit for Astorg, which had held a 60% stake in the company since 2007. The strategic rationale for the acquisition centers on supporting Ethypharm's international expansion and its leadership in specialized therapeutic areas such as pain management and addiction treatment. The transaction was supported by an "all senior" debt financing structure composed of Tranche A and Tranche B facilities. This investment follows a period of significant growth for Ethypharm, which recently expanded its footprint in the United Kingdom through the acquisition of DB Ashbourne. PAI Partners intends to leverage the target's sophisticated galenic technology and established global partnership network to drive further organic and inorganic growth. The deal reflects a significant step up in valuation for the group, highlighting the increased market demand for specialized pharmaceutical platforms with high technical barriers to entry.